GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Semaglutide - OZEMPIC subcutaneous injection

Read renal action and limits
Local official-label summarySource retrieved 2026-11-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

OZEMPIC / semaglutide / semaglutide Ozempic

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

OZEMPIC: source applicability and renal evidence limits

Baseline no-adjustment guidance and volume-depletion AKI warnings address different questions. Retain both; do not substitute another semaglutide formulation or brand.

Before applying: Monitor kidney function with volume-depleting reactions, especially during initiation/escalation.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

OZEMPIC: selected primary-label renal guidance and limits

This source only - not a merged recommendation

What matters first

Product: Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.

Renal action / finding
No renal dose adjustment recommended.
Evidence or dialysis limit
Kidney-failure PK evidence is not a modality-specific dialysis schedule.
Monitoring / application
Monitor kidney function with volume-depleting reactions, especially during initiation/escalation.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population
Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.
Renal measure
Qualitative renal categories including kidney failure; no new renal threshold
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07 (not the revision date)
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Kidney-failure PK evidence is not a modality-specific dialysis schedule.

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Sections 8.6 and 5.6

No dose adjustment is recommended for renal impairment, including kidney failure in the supporting PK evidence. Monitor renal function when adverse reactions can cause volume depletion, especially during initiation or escalation. The no-adjustment statement does not eliminate dehydration-related AKI risk or establish interchangeable dosing across semaglutide products.

Source revision: Revision date not captured in selected review; retrieval date is not revision date. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

Scope: Selected sections checked against the identified source; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

OZEMPIC: selected primary-label renal guidance and limits

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

OZEMPIC: selected RX renal passage

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

OZEMPIC: selected primary-label renal guidance and limits

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Kidney-failure PK evidence is not a modality-specific dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.

Renal method: Qualitative renal categories including kidney failure; no new renal threshold
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

OZEMPIC: selected RX renal passage

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Kidney-failure PK evidence is not a modality-specific dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.

Renal method: Qualitative renal categories including kidney failure; no new renal threshold
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

OZEMPIC: source applicability and renal evidence limits

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

OZEMPIC: source applicability and renal evidence limits

Baseline no-adjustment guidance and volume-depletion AKI warnings address different questions. Retain both; do not substitute another semaglutide formulation or brand.

How to use this: Monitor kidney function with volume-depleting reactions, especially during initiation/escalation.

OZEMPIC: selected primary-label renal guidance and limitsOZEMPIC: selected RX renal passage

Selected-source comparison; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

OZEMPIC: selected primary-label renal guidance and limits

Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.

Method: Qualitative renal categories including kidney failure; no new renal threshold

Read this complete source summary
Rxlist source

OZEMPIC: selected RX renal passage

Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.

Method: Qualitative renal categories including kidney failure; no new renal threshold

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeOZEMPIC: selected primary-label renal guidance and limitsOZEMPIC: selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

An RX mirror and its underlying label are not independent clinical confirmations.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79

Product identity and scope

Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.

RDM72-semaglutide-ozempic-scope · Source section: Product identity and scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

OZEMPIC: selected primary-label renal guidance and limits

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.

Renal method: Qualitative renal categories including kidney failure; no new renal threshold
Source date: Revision date not captured in selected review; retrieval date is not revision date.
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Kidney-failure PK evidence is not a modality-specific dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Sections 8.6 and 5.6

No dose adjustment is recommended for renal impairment, including kidney failure in the supporting PK evidence. Monitor renal function when adverse reactions can cause volume depletion, especially during initiation or escalation. The no-adjustment statement does not eliminate dehydration-related AKI risk or establish interchangeable dosing across semaglutide products.

RDM72-semaglutide-ozempic-label-1 · Source locator: Sections 8.6 and 5.6

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
Retrieved
2026-11-07
Renal-function method
Qualitative renal categories including kidney failure; no new renal threshold
Source date/version
Revision date not captured in selected review; retrieval date is not revision date.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
ac9c5c07284ad2572da17ba63eea93b8a17efc8902aff6ec57fbf9c077e2ea22
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

OZEMPIC: selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.

Renal method: Qualitative renal categories including kidney failure; no new renal threshold
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

Kidney-failure PK evidence is not a modality-specific dialysis schedule.

Dialysis evidence: No dialysis regimen established in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Sections 8.6 and 5.6

The mirror reports no renal adjustment, including kidney failure in PK evidence. Baseline dose guidance does not remove monitoring for dehydration and worsening renal function.

RDM72-semaglutide-ozempic-rx-1 · Source locator: Sections 8.6 and 5.6

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/ozempic-drug/
Retrieved
2026-11-07
Renal-function method
Qualitative renal categories including kidney failure; no new renal threshold
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
ad50d47a5f6b3e5fa626f3dcee736a9e25f821a3f83d3a935caf2153839f566d

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
Source retrieval
2026-11-07. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
1a827306ec7e8cda2b663bf7a71c2a40ca96a8b3079ec77750ac5808a20d354d
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top